London · Delayed Price · Currency is GBP · Price in SEK Medivir AB Statistics
Total Valuation
Medivir AB has a market cap or net worth of GBP 3.40 million. The enterprise value is 2.06 million.
| Market Cap | 3.40M |
| Enterprise Value | 2.06M |
Important Dates
The next estimated earnings date is Wednesday, February 18, 2026.
| Earnings Date | Feb 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 112.17M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +10.61% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.90% |
| Owned by Institutions (%) | 33.34% |
| Float | 91.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.80 |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.33 |
| EV / Sales | 6.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.46, with a Debt / Equity ratio of 0.10.
| Current Ratio | 0.46 |
| Quick Ratio | 0.46 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.87 |
Financial Efficiency
Return on equity (ROE) is -75.11% and return on invested capital (ROIC) is -43.51%.
| Return on Equity (ROE) | -75.11% |
| Return on Assets (ROA) | -29.01% |
| Return on Invested Capital (ROIC) | -43.51% |
| Return on Capital Employed (ROCE) | -107.86% |
| Revenue Per Employee | 31,454 |
| Profits Per Employee | -614,373 |
| Employee Count | 10 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.35% in the last 52 weeks. The beta is 0.33, so Medivir AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -84.35% |
| 50-Day Moving Average | 2.30 |
| 200-Day Moving Average | 21.13 |
| Relative Strength Index (RSI) | 22.32 |
| Average Volume (20 Days) | 16,168 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medivir AB had revenue of GBP 314,541 and -6.14 million in losses. Loss per share was -0.05.
| Revenue | 314,541 |
| Gross Profit | -3.78M |
| Operating Income | -6.14M |
| Pretax Income | -6.14M |
| Net Income | -6.14M |
| EBITDA | -6.13M |
| EBIT | -6.14M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 1.86 million in cash and 528,972 in debt, giving a net cash position of 1.33 million.
| Cash & Cash Equivalents | 1.86M |
| Total Debt | 528,972 |
| Net Cash | 1.33M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.16M |
| Book Value Per Share | 0.05 |
| Working Capital | -2.51M |
Cash Flow
| Operating Cash Flow | -7.61M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,952.06% |
| Pretax Margin | -1,953.24% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medivir AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.61% |
| Shareholder Yield | -10.61% |
| Earnings Yield | -180.88% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medivir AB has an Altman Z-Score of -9.81 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.81 |
| Piotroski F-Score | 1 |